Literature DB >> 28203406

Effects of recombinant human brain natriuretic peptide on the prognosis of patients with acute anterior myocardial infarction undergoing primary percutaneous coronary intervention: a prospective, multi-center, randomized clinical trial.

Zhi-Lin Miao1, Ai-Jie Hou1, Hong-Yun Zang2, Ru-Gang Huang3, Xiao-Qun Zheng4, Hai-Long Lin4, Wei Wang5, Ping Hou6, Fei Xia1, Zhan-Quan Li1.   

Abstract

BACKGROUND: This study aims to investigate the effects of recombinant human brain natriuretic peptide (rhBNP) on serum enzyme data, cardiac function parameters and cardiovascular events in patients with acute anterior myocardial infarction (MI).
METHODS: A total of 421 patients with acute anterior or extensive anterior MI were collected from 20 hospitals. These patients were randomly divided into two groups: rhBNP and control groups. Both groups of patients received primary percutaneous coronary intervention (PCI) within the effective time window. In the rhBNP group, rhBNP administration (0.01 µg/kg/min, 48-72 successive hours) was performed as early as possible after hospital admission. Prior to and one or seven days after PCI, serum concentrations of cardiac troponin (cTnT), creatine kinase-MB (CK-MB) and N-terminal pro-brain natriuretic peptide (NT-proBNP) were measured. At seven days and 6 months after PCI, left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDd) and stroke volume (SV) were measured using 2D Doppler echocardiography. MACEs that occurred during hospitalization and within 6 months after PCI were recorded.
RESULTS: At postoperative days one and seven, serum concentrations of cTnT were significantly lower in the rhBNP group than in the control group. At postoperative day one, serum concentrations of CK-MB were significantly lower in the rhBNP group than in the control group. At postoperative day seven, serum concentrations of NT-proBNP were significantly lower in the rhBNP group than in the control group, and LVEF was significantly greater in the rhBNP group than in the control group. At postoperative 6 months, LVEDd was significantly lower in the rhBNP group compared with the control group. In addition, SV and LVEF were significantly greater in the rhBNP group than in the control group. By postoperative month 6, the incidence of composite cardiovascular events (16.0% vs. 26.0%, P=0.012), cardiac death (7.0% vs.13.5%, P=0.030), and particularly cardiac death + re-hospitalization for congestive heart failure (13.1% vs. 25.5%, P=0.001) were significantly lower in the rhBNP group than in the control group.
CONCLUSIONS: Early intravenous rhBNP administration after PCI significantly lowered the serum concentrations of cTnT and NT-proBNP, increased LVEDd, SV and LVEF, and reduced MACEs, including cardiac death, in patients with acute anterior MI undergoing PCI.

Entities:  

Keywords:  Acute anterior myocardial infarction; N-terminal pro-brain natriuretic peptide (NT-proBNP); major adverse event; percutaneous coronary intervention (PCI); recombinant human brain natriuretic peptide

Year:  2017        PMID: 28203406      PMCID: PMC5303080          DOI: 10.21037/jtd.2017.01.15

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  27 in total

1.  [Guideline for diagnosis and treatment of patients with ST-elevation myocardial infarction].

Authors: 
Journal:  Zhonghua Xin Xue Guan Bing Za Zhi       Date:  2010-08

Review 2.  Clinical applications of B-type natriuretic peptide levels in the care of cardiovascular patients.

Authors:  P A McCullough
Journal:  Minerva Cardioangiol       Date:  2004-12       Impact factor: 1.347

3.  B-type natriuretic peptide for prevention of contrast-induced nephropathy in patients with heart failure undergoing primary percutaneous coronary intervention.

Authors:  Jing Zhang; Xianghua Fu; Xinwei Jia; Xinna Fan; Xinshun Gu; Shiqiang Li; Weili Wu; Weize Fan; Jianling Su; Guozhen Hao; Yunfa Jiang; Ling Xue
Journal:  Acta Radiol       Date:  2010-07       Impact factor: 1.990

4.  Twenty-five-year trends in myocardial infarction attack and mortality rates, and case-fatality, in six European populations.

Authors:  Irene R Dégano; Veikko Salomaa; Giovanni Veronesi; Jean Ferriéres; Inge Kirchberger; Toivo Laks; Aki S Havulinna; Jean-Bernard Ruidavets; Marco M Ferrario; Christa Meisinger; Roberto Elosua; Jaume Marrugat
Journal:  Heart       Date:  2015-04-08       Impact factor: 5.994

Review 5.  Vasopeptidase inhibition: a new concept in blood pressure management.

Authors:  J C Burnett
Journal:  J Hypertens Suppl       Date:  1999-02

6.  Administration of atrial natriuretic peptide attenuates reperfusion phenomena and preserves left ventricular regional wall motion after direct coronary angioplasty for acute myocardial infarction.

Authors:  Hideyo Kuga; Kenichi Ogawa; Akitugu Oida; Isao Taguchi; Masatoshi Nakatsugawa; Toshiyasu Hoshi; Hiroyasu Sugimura; Shichirou Abe; Noboru Kaneko
Journal:  Circ J       Date:  2003-05       Impact factor: 2.993

7.  Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials.

Authors:  Masafumi Kitakaze; Masanori Asakura; Jiyoong Kim; Yasunori Shintani; Hiroshi Asanuma; Toshimitsu Hamasaki; Osamu Seguchi; Masafumi Myoishi; Tetsuo Minamino; Takahiro Ohara; Yoshiyuki Nagai; Shinsuke Nanto; Kouki Watanabe; Shigeru Fukuzawa; Atsushi Hirayama; Natsuki Nakamura; Kazuo Kimura; Kenshi Fujii; Masaharu Ishihara; Yoshihiko Saito; Hitonobu Tomoike; Soichiro Kitamura
Journal:  Lancet       Date:  2007-10-27       Impact factor: 79.321

Review 8.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

Authors:  Ellen C Keeley; Judith A Boura; Cindy L Grines
Journal:  Lancet       Date:  2003-01-04       Impact factor: 79.321

9.  All-trans retinoic acid stimulates gene expression of the cardioprotective natriuretic peptide system and prevents fibrosis and apoptosis in cardiomyocytes of obese ob/ob mice.

Authors:  Daniel-Constantin Manolescu; Marek Jankowski; Bogdan A Danalache; Donghao Wang; Tom L Broderick; Jean-Louis Chiasson; Jolanta Gutkowska
Journal:  Appl Physiol Nutr Metab       Date:  2014-04-30       Impact factor: 2.665

Review 10.  The new biology of aldosterone.

Authors:  John M C Connell; Eleanor Davies
Journal:  J Endocrinol       Date:  2005-07       Impact factor: 4.286

View more
  2 in total

1.  The Protective Effect of rhBNP on Postresuscitation Myocardial Dysfunction in a Rat Cardiac Arrest Model.

Authors:  Min Yang; Tianfeng Hua; Zhengfei Yang; Limin Chen; Yangyang Zou; Xiaohui Huang; Jun Li
Journal:  Biomed Res Int       Date:  2020-02-17       Impact factor: 3.411

2.  Effects of recombinant human brain natriuretic peptide in patients with acute myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta-analysis.

Authors:  Cheng Ning; Yawei Zheng; Jie Li; Ming Liu; Zhuyuan Fang
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.